MedTrace Logo

Paediatric Pneumococcal Pneumonia in Malaysia Prior to and During Pneumococcal Conjugate Vaccine (PCV) Implementation

NCT04923035 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 1010

Last updated 2024-01-18

No results posted yet for this study

Summary

The purpose of this research is to provide baseline surveillance of pneumonia in young children in Malaysia before and during the implementation of the pneumococcal conjugate vaccine (PCV). Pneumonia is a respiratory infection that can cause mild to life-threatening disease among all age groups but is the leading infectious cause of death among children globally. The most common cause of pneumonia is infection with a bacteria called Streptococcus pneumoniae, also known as pneumococcus. Hence, immunisation with a pneumococcal vaccine is an effective way to prevent pneumonia. In Malaysia, pneumococcal vaccination under the National Immunisation Programme (NIP) for children has since commenced in December 2020, comprising of 3 doses at four, six and 15 months. The routine use of PCV in children will contribute to reducing the burden of pneumococcal infections in the country, especially severe infections. The ongoing COVID-19 pandemic may also have implications on the pneumococcal serotype and clinical presentation of infections in the community.

Conditions

  • Pneumonia, Pneumococcal
  • Pneumonia Childhood

Sponsors & Collaborators

  • University of Malaya

    collaborator OTHER

  • Universiti Sains Malaysia

    collaborator OTHER

  • International Islamic University Malaysia

    collaborator OTHER

  • University of Southampton

    collaborator OTHER

  • Merck Sharp & Dohme LLC

    collaborator INDUSTRY

  • IMU University, Malaysia

    lead OTHER

Principal Investigators

  • Lokman Hakim H Sulaiman, PhD · IMU University, Malaysia

Eligibility

Min Age
1 Month
Max Age
5 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-10-13
Primary Completion
2023-08-29
Completion
2024-12-31

Countries

  • Malaysia

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04923035 on ClinicalTrials.gov